Toxin-based targeted therapy for malignant brain tumors.
Toxin-based targeted therapy for malignant brain tumors.
复制标题
DOI：
10.1155/2012/480429
复制
发表时间：
2012
影响因子：
--
通讯作者：
Bigner DD
中科院分区：
文献类型：
--
作者：
Chandramohan V;Sampson JH;Pastan I;Bigner DD
尽管恶性脑肿瘤的传统治疗方式取得了进展，如手术、放疗和化疗，但高级别星形细胞肿瘤患者的预后仍然很差。星形细胞肿瘤的高度异质性和弥漫性要求开发新的治疗方法。基因组学和蛋白质组学研究的进展表明，脑肿瘤患者的治疗可以根据靶向肿瘤及其环境的特征越来越个性化。因此，在过去二十年中，出现了一类新型用于治疗中枢神经系统肿瘤的研究候选药物：配备针对肿瘤特异性抗原的细胞毒性剂的重组融合蛋白缀合物。肿瘤抗原导向的细胞毒性蛋白作为一种安全可行的脑肿瘤治疗方法的临床适用性正在研究中。迄今为止，正在进行的临床试验的结果令人鼓舞，因为在至少109例病例中观察到疾病稳定和患者生存期延长。本文总结了在临床前和临床阶段与不同的抗胶质瘤细胞毒素治疗有关的主要发现。
Despite advances in conventional treatment modalities for malignant brain tumors—surgery, radiotherapy, and chemotherapy—the prognosis for patients with high-grade astrocytic tumor remains dismal. The highly heterogeneous and diffuse nature of astrocytic tumors calls for the development of novel therapies. Advances in genomic and proteomic research indicate that treatment of brain tumor patients can be increasingly personalized according to the characteristics of the targeted tumor and its environment. Consequently, during the last two decades, a novel class of investigative drug candidates for the treatment of central nervous system neoplasia has emerged: recombinant fusion protein conjugates armed with cytotoxic agents targeting tumor-specific antigens. The clinical applicability of the tumor-antigen-directed cytotoxic proteins as a safe and viable therapy for brain tumors is being investigated. Thus far, results from ongoing clinical trials are encouraging, as disease stabilization and patient survival prolongation have been observed in at least 109 cases. This paper summarizes the major findings pertaining to treatment with the different antiglioma cytotoxins at the preclinical and clinical stages.
登录
查看更多内容
影响因子：
3.7
作者：
EIKLID, K;OLSNES, S;PIHL, A
通讯作者：
PIHL, A
影响因子：
4.1
作者：
ARITA, N;HAYAKAWA, T;MOGAMI, H
通讯作者：
MOGAMI, H
影响因子：
64.5
作者：
DERYNCK, R;ROBERTS, AB;GOEDDEL, DV
通讯作者：
GOEDDEL, DV
影响因子：
3.9
作者：
BIGNER, DD;BROWN, M;ZALUTSKY, MR
通讯作者：
ZALUTSKY, MR
影响因子：
158.5
作者：
CONSTINE, LS;WOOLF, PD;RUBIN, P
通讯作者：
RUBIN, P